SIETES :: 92381 citas

Resultados de la búsqueda por VÍA INTRAVENOSA REFINAR BÚSQUEDA

1.

Lee-HY, Ban G-Y, Jeong C-G, Lee JH, Park SH, Kim SH, Lee Y-H, Ye Y-M. Propacetamol poses a potential harm of adverse hypotension in male and older patients. Pharmacoepidemiol Drug Saf 2017;26:256-64. [Ref.ID 102062]

2.

Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]

3.

Wang C, Wong S, Graham DJ. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232-3. [Ref.ID 100367]

4.

DeLoughery TG. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232. [Ref.ID 100366]

5.

Pathan SA, Mitra B, Straney LD, Afzal MS, Anjum S, Shukla D, Morley K, Al Hilli SA, Al Rumaihi K, Thomas SH, Cameron PA. Delivering safe and effective analgesia for management of renal colic in the emergency department: a double-blind, multigroup, randomised controlled trial. Lancet 2016;387:1999-2007. [Ref.ID 100295]

6.

Knoedler JJ, Lieske JC. Non-steroidal anti-inflammatory drugs for renal colic. Lancet 2016;387:1971-2. [Ref.ID 100294]

7.

Jian Z, Li H, Race NS, Ma T, Jin H, Yin Z. Is the Era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers? meta-analysis of the published literature.. Br J Clin Pharmacol 2015:18 de diciembre. [Ref.ID 99821]

8.

Connors JM. Antidote for factor Xa anticoagulants. N Engl J Med 2015;373:2471-2. [Ref.ID 99801]

9.

Wang C, Graham DJ, Kane RC, Xie D, Wemecke M, Levenson M, MaCurdy TE, Houstoun M, Ryan Q, Wong S, Mott K, Sheu T-C, Limb S, Worrall C, Kelman JA, Reichman ME. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015;314:2062-8. [Ref.ID 99687]

10.

Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413-24. [Ref.ID 99658]

11.

Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G, COPOUSEP investigators West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015;386:974-81. [Ref.ID 99529]

12.

Sánchez-González R, Ternavasio-de la Vega H, Moralejo Alonso L, Revuelta SI, Fuertes Martín A. Hipofosfatemia asociada a la administración intravenosa de hierro carboximaltosa en pacientes con anemia ferropénica. Un efecto secundario frecuente. Med Clin (Barc) 2015;145:108-11. [Ref.ID 99378]

13.

Anónimo. Drug-administering pump can be hacked, FDA warns. DIA Daily 2015:1. [Ref.ID 99372]

14.

Glyn-Jones S, Palmer AJR, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ. Osteoarthritis. Lancet 2015;386:376-87. [Ref.ID 99368]

15.

Freedberg DE, Salmasian H, Abrams JA, Green RA. Orders for intravenous proton pump inhibitors after implementation of an electronic alert. JAMA Intern Med 2015;175:452-4. [Ref.ID 98971]

16.

Anónimo. FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). FDA U.S. Food and Drug Administration 2015:30 de marzo. [Ref.ID 98888]

17.

Anónimo. Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. Med Lett Drugs Ther 2015;57:17-9. [Ref.ID 98855]

18.

Anónimo. Oritavancin (Orbactiv) for skin and skin structure infections. Med Lett Drugs Ther 2015;57:3-5. [Ref.ID 98698]

19.

Anónimo. FDA approves Rapivab to treat flu infection. FDA U.S. Food and Drug Administration 2014:1. [Ref.ID 98394]

20.

Anónimo. FDA approves Orbactiv to treat skin infections. FDA U.S. Food and Drug Administration 2014:6 de agosto. [Ref.ID 97853]